Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Phosphodiesterase 4D (PDE4D) mRNA 3' untranslated region (3'UTR) is a critical regulatory segment of the messenger RNA encoding the PDE4D enzyme, which is responsible for the hydrolysis of the second messenger cyclic AMP (cAMP). This region contains multiple binding sites for regulatory proteins and microRNAs that control the stability and translation efficiency of the PDE4D transcript (Richter et al., 2015). A key biological interaction involves the Fragile X Mental Retardation Protein (FMRP), which binds to the PDE4D 3'UTR to suppress its translation; the loss of this regulation is a primary driver of the low cAMP levels observed in Fragile X Syndrome (Gurney et al., 2017). Additionally, microRNAs such as miR-139-5p and miR-214 target this region to downregulate PDE4D expression in various pathological contexts, including cancer and ischemic stroke (Qu et al., 2015; Wang et al., 2021). While current clinical strategies primarily utilize small molecule inhibitors to target the PDE4D enzyme itself, the 3'UTR represents an emerging target for RNA-based therapeutics, such as antisense oligonucleotides (ASOs) or microRNA mimics, aimed at restoring physiological protein levels. Targeting this region offers the potential for high isoform specificity, potentially avoiding the side effects associated with broad phosphodiesterase inhibition.
Modulation of mRNA stability or translation efficiency through competitive binding or recruitment of the RNA-induced silencing complex (RISC) to specific motifs within the 3'UTR.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphodiesterase 4D messenger RNA 3' untranslated region (PDE4D mRNA 3'UTR).